Buscar por Autor Martín Lluesma, Silvia

Ir a: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
O introducir las primeras letras:  
Resultados 1 a 7 de 7
Vista previaFecha de publicaciónTítuloAutor(es)Tipo
Dendritic_Martin_et_al_COBIOT_.pdf.jpg2020Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?Martín Lluesma, Silvia; Graciotti, Michele; Grimm, Alizée J.; Boudousquié, Caroline; Chiang, Cheryl L.; Kandalaft, Lana E.Artículo
Immunocompetent_Martin_et_al_Vaccines_2018.pdf.jpg23-nov-2018Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?Martín Lluesma, Silvia; Graciotti, Michele; Chiang, Cheryl L.; Kandalaft, Lana E.Artículo
Efficacy_Dafni_et_al_An_Onc_2019.pdf.jpg1-dic-2019Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysisDafni, Urari; Michielin, O.; Martín Lluesma, Silvia; Tsourti, Z.; Polydoropoulou, V.; Karlis, D.; Besser, M. J.; Haanen, J.; Svane, I. M.; Ohashi, P. S.; Kammula, U. S; Orcurto, A.; Zimmermann, Sabine D.; Trueb, L.; Klebanoff, C. A.; Lotze, M. T.; Kandalaft, Lana E.; Coukos, GeorgeArtículo
Efficacy_Dafni_et_al_EurJCancer_2021.pdf.jpg2021Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysisDafni, Urari; Martín Lluesma, Silvia; Balint, Klara; Tsourti, Z.; Vervita, K.; Chenal, J.; Coukos, George; Zaman, Khalil; Sarivalasis, Apostolos; Kandalaft, Lana E.Artículo
Emerging_Tsoutsou_et_al_Front_Onco_2018.pdf.jpg12-dic-2018Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer HeterogeneityTsoutsou, Pelagia G.; Zaman, Khalil; Martín Lluesma, Silvia; Cagnon, Laurene; Kandalaft, Lana E.; Vozenin, Marie CatherineArtículo
Phase_Sarivalasis_et_al_JTranslMed_2019.pdf.jpg26-nov-2019A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP‑DC) or with tumor lysate (OC‑DC) in patients with advanced high‑grade ovarian serous carcinomaSarivalasis, Apostolos; Boudousquié, Caroline; Balint, Klara; Stevenson, Brian J.; Gannon, Philippe O.; Ianco, Emanuela Marina; Rossier, Laetitia; Martín Lluesma, Silvia; Mathevet, Patrice; Semphoux, Christine; Coukos, George; Dafni, Urari; Harari, Alexandre; Bassani Sternberg, Michal; Kandalaft, Lana E.Artículo
Phase_Ib_Bassani_et_al_Fron_Inm_2019.pdf.jpg8-ago-2019A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma-A Proof of Antigen Discovery Feasibility in Three PatientsBassani Sternberg, Michal; Digklia, A.; Huber, F.; Wagner, D.; Sempoux, C.; Stevenson, Brian J.; Thierry, Anne Christine; Michaux, Justine; Pak, HuiSong; Balint, Klara; Gfeller, David; Martín Lluesma, Silvia; Dermatines, Nicolas; Kandalaft, Lana E.; Racle, Julien; Boundousquie, Caroline; Coukos, George; Harari, AlexandreArtículo